Biotherapies in large vessel vasculitis

被引：50

作者：

Ferfar, Y. ^{[1
]}

Mirault, T. ^{[2
]}

Desbois, A. C. ^{[1
]}

Comarmond, C. ^{[1
]}

Messas, E. ^{[2
]}

Savey, L. ^{[1
]}

Domont, F. ^{[1
]}

Cacoub, P. ^{[1
]}

Saadoun, D. ^{[1
]}

机构：

[1] Univ Paris 06, Grp Hosp Pitie Salpetriere, AP HP,Serv Med Interne & Immunol Clin,DHU I2B, Ctr Reference Malad Autoimmunes & Syst Rares,Immu, Paris, France

[2] Grp Hosp HEGP, AP HP, Serv Med Vasc, Ctr Natl Reference Malad Vasc Rares, Paris, France

来源：

AUTOIMMUNITY REVIEWS | 2016年 / 15卷 / 06期

关键词：

Giant cell arteritis; Takayasu; Behcet's disease; Relapsing polychondritis; Biotherapy; GIANT-CELL ARTERITIS; REFRACTORY TAKAYASU ARTERITIS; PLACEBO-CONTROLLED TRIAL; NECROSIS FACTOR THERAPY; ANTI-TNF-ALPHA; RELAPSING POLYCHONDRITIS; BEHCETS-DISEASE; POLYMYALGIA-RHEUMATICA; EULAR RECOMMENDATIONS; SUSTAINED RESPONSE;

D O I：

10.1016/j.autrev.2016.02.012

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Giant cell arteritis (GCA) and Takayasu's arteritis (TA) are large vessel vasculitis (LW) and aortic involvement is not uncommon in Behcet's disease (BD) and relapsing polychondritis (RP). Glucocorticosteroids are the mainstay of therapy in LW. However, a significant proportion of patients have glucocorticoid dependance, serious side effects or refractory disease to steroids and other immunosuppressive treatments such as cyclophosphamide, azathioprine, mycophenolate mofetil and methotrexate. Recent advances in the understanding of the pathogenesis have resulted in the use of biological agents in patients with LW. Anti-tumor necrosis factor-alpha drugs seem effective in patients with refractory Takayasu arteritis and vascular BD but have failed to do so in giant cell arteritis. Preliminary reports on the use of the anti-IL6-receptor antibody (tocilizumab), in LW have been encouraging. The development of new biologic targeted therapies will probably open a promising future for patients with LW. (C) 2016 Elsevier B.V. All rights reserved.

引用

页码：544 / 551

页数：8

共 50 条

[1] Biotherapies in large vessel vasculitis
Pazzola, G.
Muratore, F.
Pipitone, N.
Salvarani, C.
REVUE DE MEDECINE INTERNE, 2016, 37 (04): : 274 - 278
[2] Current and emerging therapies in large-vessel vasculitis
Kermani, Tanaz A.
Dasgupta, Bhaskar
RHEUMATOLOGY, 2018, 57 (09) : 1513 - 1524
[3] Comparing treatment options for large vessel vasculitis
Macaluso, Federica
Marvisi, Chiara
Castrignano, Paola
Pipitone, Nicolo
Salvarani, Carlo
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (08) : 793 - 805
[4] Advances and challenges in management of large vessel vasculitis
Chu, Cong-Qiu
RHEUMATOLOGY AND IMMUNOLOGY RESEARCH, 2023, 4 (04): : 188 - 195
[5] Large-vessel vasculitis
Pugh, Dan
Karabayas, Maira
Basu, Neil
Cid, Maria C.
Goel, Ruchika
Goodyear, Carl S.
Grayson, Peter C.
McAdoo, Stephen P.
Mason, Justin C.
Owen, Catherine
Weyand, Cornelia M.
Youngstein, Taryn
Dhaun, Neeraj
NATURE REVIEWS DISEASE PRIMERS, 2022, 7 (01)
[6] Methotrexate treatment in large vessel vasculitis and polymyalgia rheumatica
Spies, C. M.
Burmester, G-R.
Buttgereit, F.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (05) : S172 - S177
[7] New Therapeutic Approaches to Large-Vessel Vasculitis
Kaymakci, Mahmut S.
Warrington, Kenneth J.
Kermani, Tanaz A.
ANNUAL REVIEW OF MEDICINE, 2024, 75 : 427 - 442
[8] Large vessel vasculitis
Caspary, L.
Schellong, S.
INTERNIST, 2009, 50 (08): : 958 - 963
[9] Molecular imaging of large vessel vasculitis
Regis, Claudine
Abikhzer, Gad
Harel, Francois
Pelletier-Galarneau, Matthieu
JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES, 2024, 55 (02) : S10 - S16
[10] Management of large-vessel vasculitis
Salvarani, Carlo
Hatemi, Gulen
CURRENT OPINION IN RHEUMATOLOGY, 2019, 31 (01) : 25 - 31

← 1 2 3 4 5 →